Professor Eric Y.F. WAN 尹旭輝
Assistant Professor
- BSc, MSc, PhD
Biography
Professor Eric Wan is jointly appointed by the Department of Family Medicine and Primary Care, and the Department of Pharmacology and Pharmacy of The University of Hong Kong. He obtained his degree of BSc in Computing Mathematics with First Class Honour from the City University of Hong Kong and MSc in Statistics with Distinction from the University of Nottingham in UK. Following the completion of his PhD in Primary Care and Medical Statistics from the University of Hong Kong, he worked as a medical statistician in the University of Oxford. He was also a Chartered Statistician (CStat) from the Royal Statistical Society, and a Professional Statistician (PStat®) from the American Statistical Association. He was also awarded the Health and Medical Research Fund Research Fellowship of the Health Bureau of Hong Kong SAR Government as a visiting scholar at the Harvard University. His achievements are recognised from funding bodies including National Natural Science Foundation of China (NSFC) Excellent Young Scientists Fund (Hong Kong and Macau), and awards including the HKU Faculty Outstanding Research Output Award.
Professor Wan is an experienced epidemiologist and medical statistician, and has published more than 150 articles in international journals including top-tier specialty journals such as Annals of Internal Medicine, Lancet Infectious Disease, The Lancet Healthy Longevity, Journal of the American College of Cardiology, Cardiovascular Research, Diabetes Care and Hypertension. His expertise is using big data analytics in health and health service research. He has been awarded several competitive grants as principal investigator or co- principal investigator including the Health and Medical Research Fund of the Food and Health Bureau of Hong Kong SAR Government, RGC Collaborative Research Fund and Beat Drug Fund. He is a Co-principal investigator of AI and Pharmaceuticals in Non-Communicable Diseases at the Laboratory of Data Discovery for Health (D²4H). He is one of the lead researchers in the CARE Programme, a comprehensive surveillance programme to monitor known and potential adverse events of COVID-19 vaccines in Hong Kong. He is also a member of NeuroGEN (Neurological and Mental Health Global Epidemiology Network) and Institute of Cardiovascular Science and Medicine, and an affiliate member of Hong Kong College of Family Physicians.
Professor Wan was featured in a Radio Television Hong Kong (RTHK) programme titled Hong Kong Stories: Inventors in Hong Kong – Treasure Hunting in Big Data. In this programme, Dr Wan shared when his passion for numbers began and how it helped kickstart his career with big data and medical statistics, and also showcased the importance of big data analytics on health services and COVID-19. His recent research focuses on 1) epidemiology in hypertension, diabetes and multi-morbidity; 2) effectiveness of pharmacotherapy in particular antidiabetic drugs, antihypertensive drugs and lipid lowering agents using target trial emulation; 3) effectiveness and cost-effectiveness of primary care health services.
Memberships & Editorships
Membership
- Member of American Statistical Association
- Member of Royal Statistical Society
- Member of NeuroGEN (Neurological and Mental Health Global Epidemiology Network)
- Member of Institute of Cardiovascular Science and Medicine
- Affiliate member of Hong Kong College of Family Physicians.
Editorship
- Corresponding Editor for Statistics of Journal of Orthopaedic Surgery
Honours and Awards
- NSFC Excellent Young Scientists Fund (Hong Kong and Macau), National Natural Science Foundation of China (NSFC), 2022
- HKU Faculty of Medicine Outstanding Research Output Award (First author), 2022, on the paper titled “Analysis of Bell's Palsy Following Vaccination with mRNA (Comirnaty) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.”
- Best Research Paper Award at Hong Kong Primary Care Conference (First author), Hong Kong College of Family Physicians, 2020, on the paper titled “Is chronic kidney disease equally important as cardiovascular disease in 3 million adults? A 10-year retrospective cohort study.”
- Hong Kong College of Family Physicians (HKCFP) Best Research Award (First author), Hong Kong College of Family Physicians, 2019, on the paper titled “Relative importance, healthy life-year lost and population attributable risk of modifiable risk factors on cardiovascular disease in a 10-year Diabetes Cohort.”
- Best Research Paper Award of the 4th AMM-AMS-HKAM Tripartite Congress cum 53rd Singapore-Malaysia Congress of Medicine & Hong Kong Primary Care Conference (First author), Academy of Medicine of Malaysia, Academy of Medicine of Singapore, Hong Kong Academy of Medicine, Hong Kong College of Family Physicians, 2019 on the paper titled “Burden of chronic kidney and cardiovascular diseases on life expectancy and health service utilization - A cohort study of Hong Kong Chinese hypertensive patients.”
- HKU Faculty of Medicine Outstanding Research Output Award (First author), 2019, on the paper titled “Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme–Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses—A Population-Based and Propensity-Matched Cohort Study.”
- Best Contribution to Family Medicine Award (First author), World Organization of Family Doctors (WONCA), 2018, on the paper titled “Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme–Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses—A Population-Based and Propensity-Matched Cohort Study.”
- 1st Distinguished Research Making Family Medicine Shine Award (First author), World Organization of Family Doctors (WONCA), 2018, on the paper titled “Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme–Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses—A Population-Based and Propensity-Matched Cohort Study.”
Research Interests
- Epidemiology in non-communicable diseases including hypertension, diabetes and multimorbidity;
- Evaluation of effectiveness of pharmacotherapy in particular antidiabetic drugs, antihypertensive drugs and lipid lowering agents using target trial emulation;
- Evaluation of effectiveness and cost-effectiveness of primary care health services;
Publications
Publication Highlights
-
Eric YF Wan, Vincent KC Yan, Anna HY Mok, Boyuan Wang, Wanchun Xu, Franco WT Cheng, Francisco TT Lai, Celine SL Chui, Xue Li, Carlos KH Wong, Philip H Li, Benjamin J Cowling, Ivan FN Hung, Chak S Lau, Ian CK Wong, Esther WY Chan. Effectiveness of molnupiravir and nirmatrelvir-ritonavir in hospitalized COVID-19 patients: A Target Trial Emulation Study. Annals of Internal Medicine. 2023 doi: https://doi.org/10.7326/M22-3057
Impact Factor (2021): 51.598, Rank: 6/172 in Medicine, General & Internal
This study showed molnupiravir and nirmatrelvir–ritonavir reduced all-cause mortality in both vaccinated and unvaccinated hospitalized patients. No significant reduction in ICU admission or the need for ventilatory support was observed. We are the first to use standard method of target trial emulation in Hong Kong. This study has been ranked excellent evidence rating level in 2 Minute Medicine, which is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors. -
Eric YF Wan; Sukriti Mathur, Ran Zhang, Vincent KC Yan; Francisco TT Lai, Celine SL Chui, Xue Li, Carlos KH Wong, Esther WY Chan, Kai Hang Yiu*, Ian CK Wong*. Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: A prospective cohort in UK Biobank. Cardiovascular Research. 2023. doi: 10.1093/cvr/cvac195
Impact Factor (2021): 14.239, (Rank: 10/143 Cardiac & cardiovascular systems)
COVID-19 infection, including long-COVID, is associated with increased short- and long-term risks of CVD and mortality. Ongoing monitoring of signs and symptoms of developing these cardiovascular complications post diagnosis and up till at least a year post recovery may benefit infected patients, especially those with severe disease. This work was selected for press release by the European Society of Cardiology. This finding has received more than 100 mentions in both local and international media, and has been referenced in more than 2,000 posts on social media. This paper is 3 out 4,073 highest-scoring outputs from Cardiovascular Research. -
KS Chan, Eric YF Wan* (Corresponding author), WY Chin, Esther YT Yu, Ivy L Mak, Will HG Cheng, Margaret K Ho, Cindy LK Lam. Association between team-based continuity of care and risk of cardiovascular diseases among patients with diabetes: a retrospective cohort study. Diabetes Care. 2022 doi: 10.2337/dc21-1217
Impact Factor (2021): 17.155, Rank: 6/146 in Endocrinology & Metabolism
Team-based continuity of care was associated with lower CVD risk among individuals with type 2 diabetes, especially those who were younger. This suggests a potential flexible alternative implementation of continuity of care in public clinics. Our team was interviewed by Physician’s Weekly to comment on the feasibility continuity of care in diabetes management. -
Eric YF Wan, Celine SL Chui, Francisco TT Lai, Esther WY Chan, Xue Li, Vincent KC Yan, Le Gao, Qiuyan Yu, Ivan CH Lam, Raccoon KC Chung, Benjamin J Cowling, WC Fong, Alexander YL Lau, Vincent CT Mok, Frank LF Chan, CK Lee, Lot ST Chan, Dawin Lo, KK Lau, Ivan FN Hung, Gabriel M Leung, Ian CK Wong. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. The Lancet Infectious Diseases. 2021. doi: 10.1016/S1473-3099(21)00451-5
Impact Factor (2021): 71.421, Rank: 2/94 in Infectious diseases
This study concluded that the beneficial and protective effects of the inactivated COVID-19 vaccine far outweigh the risk of developing Bell’s palsy. The finding has garnered over 30 local and international media mentions, and have been cited in over 5,000 social media posts, and have awarded Outstanding Research Output Award from HKU Faculty of Medicine. This research showcased the impact of interdisciplinary collaborative efforts across HKU, the Hong Kong Hospital Authority, and the Department of Health, utilizing big clinical data analytics to generate real-world evidence for informing clinical practice. In term of policy and guideline changes, we are the first to provide evidence on the risk of Bell’s palsy subsequent to the CoronaVac vaccination. As a result of this study, Sinovac Biotech (Hong Kong) Limited gained obtained approval to include potential association of Bell’s palsy in the CoronaVac package insert globally. A similar warning has also been added to the Vaccination Fact Sheet for CoronaVac issued by the Department of Health in Hong Kong so that the vaccine recipients with the incidence of Bell’s palsy after vaccination can obtain compensation from the government in Hong Kong. -
Eric YF Wan, Colman SC Fung, Frances FF Jiao, Esther YT Yu, WY Chin, Daniel YT Fong, Carlos KH Wong, Anca KC Chan, Karina HY Chan, Ruby LP Kwok, Cindy LK Lam. Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme–Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses—A Population-Based and Propensity-Matched Cohort Study. Diabetes Care 2018; 41:49-59 doi: 10.2337/dc17-0426
Impact Factor (2021): 17.155, Rank: 6/146 in Endocrinology & Metabolism
This naturalistic study highlighted the importance of early optimal DM control and risk factor management by risk stratification and multidisciplinary, protocol-driven, chronic disease model care to delay disease progression and prevent complications. This demonstrated the impact of collaborative research between the University of Hong Kong and the Hong Kong Hospital Authority on big data analytics to generate real-world evidence to inform clinical practice. This excellent finding leads to the incorporation of this program into the diabetic management strategies of the Hong Kong Hospital Authority. The research output was selected as a "Noteworthy Innovative Article" and being cited by the chief of editor in a guide on how to use big data for diabetes research in Diabetes Care. In addition, the findings have been widely cited internationally, such as the 2019 American Cardiology Committee/American Heart Association, which rated the research results as high-quality evidence for the primary prevention guidelines of cardiovascular disease. At the same time, the American Diabetes Association has included our finding in its "Diabetes Medical Standards" in 2020, 2021, and 2022 to recommend multidisciplinary risk screening and management in diabetic management guideline.
Selected Publications
- Eric YF Wan; Boyuan Wang, Sukriti Mathur, Cheyenne IY Chan, Vincent KC Yan, Francisco TT Lai, Celine SL Chui, Xue Li, Carlos KH Wong, Philip H Li, Chak S Lau, Ian CK Wong, Esther WY Chan*. Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase. Journal of Infection. 2023 doi: 10.1016/j.jinf.2023.02.029 (IF 38.637, 4/95 in INFECTIOUS DISEASES)
- Eric YF Wan, Anna HY Mok, Vincent KC Yan, Cheyenne IY Chan, Boyuan Wang, Francisco TT Lai, Celine SL Chui, Xue Li, Carlos KH Wong, Chak S Lau, Ian CK Wong, Esther WY Chan. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 Omicron infection in people aged 60 years or above: a case-control study. Journal of Travel Medicine. 2022. doi: 10.1093/jtm/taac119 (IF 39.194, 3/95 in INFECTIOUS DISEASES)
- Eric YF Wan, Anna HY Mok, Vincent KC Yan, Boyuan Wang, Ran Zhang, Sabrina N Hong, Celine SL Chui, Xue Li, Carlos KH Wong, Francisco TT Lai, Kathryn CB Tan, Chak S Lau, Ian CK Wong, Esther WY Chan. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study. Journal of Infection. 2022. doi: 10.1016/j.jinf.2022.08. (IF 38.637, 4/95 in INFECTIOUS DISEASES )
- Eric YF Wan, Yuan Wang, Celine SL Chui, Anna HY Mok, Wanchun Xu, Vincent KC Yan, Francisco TT Lai, Xue Li, Carlos KH Wong, Esther WY Chan, Kui-Kai Lau, Benjamin J Cowling, Ivan FN Hung, Ian CK Wong. Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series. The Lancet Healthy Longevity. 2022; 3(7):e491-e500. doi: 10.1016/S2666-7568(22)00125-8 (1/67 in GERIATRICS & GERONTOLOGY )
- Eric YF Wan, Celine SL Chui, Vanessa WS Ng, Yuan Wang, Vincent KC Yan, Ivan CH Lam, Min Fan, Francisco TT Lai, Esther WY Chan, Xue Li, Carlos KH Wong, Raccoon KC Chung, Benjamin J Cowling, Wing C Fong, Alexander YL Lau, Vincent CT Mok, Frank LF Chan, Cheuk K Lee, Lot ST Chan, Dawin Lo, Kui K Lau, Ivan FN Hung, Chak S Lau, Gabriel M Leung, Ian CK Wong. mRNA (BNT162b2) COVID-19 vaccination increased risk of Bell’s palsy: a nested case control and self-controlled case series study. Clinical Infectious Diseases. 2022. doi: 10.1093/cid/ciac460 (IF 20.999, 7/162 in Immunology)
- Eric YF Wan, Celine SL Chui, Yuan Wang, Vanessa WS Ng, Vincent KC Yan, Francisco TT Lai, Xue Li, Carlos KH Wong, Esther WY Chan, Christina SM Wong, Kathy SM Leung, Michael Y Ni, Sophie A Valkenburg, Joseph S Malik Peiris, Joseph TK Wu, Benjamin J Cowling, Darren M Ashcroft, Ivan FN Hung, Gabriel M Leung, Ian CK Wong. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. The Lancet Regional Health - Western Pacific. 2022. DOI:10.1016/j.lanwpc.2022.100393 (IF 8.559, 3/109 in Health Care Sciences & Services)
- Eric YF Wan, WY Chin, Esther YT Yu, Ian CK Wong, Esther WY Chan, Shirley X Li, Nico KL Cheung, Yuan Wang, Cindy LK Lam. The impact of cardiovascular disease and chronic kidney disease on life expectancy and direct medical cost in a 10-year diabetes cohort study. Diabetes Care. 2020; doi: https://doi.org/10.2337/dc19-2137 (IF 17.155, 6/146 in Endocrinology & Metabolism)
- Eric YF Wan, WT Fung, C Mary Schooling, SL Au Yeung, Man-Ki Kwok, Esther YT Yu, Yuan Wang, Esther WY Chan, Ian CK Wong, Cindy LK Lam. Blood pressure and Risk of Cardiovascular disease in UK Biobank: A Mendelian randomization study. Hypertension. 2020. doi: 10.1161/HYPERTENSIONAHA.120.16138 (IF 9.897, 8/67 in Peripheral vascular disease)
- Eric YF Wan, Esther YT Yu, WY Chin, Daniel YT Fong, Edmond PH Choi, Eric HM Tang, Cindy LK Lam. Burden of CKD and Cardiovascular Disease on Life Expectancy and Health Service Utilization: a Cohort Study of Hong Kong Chinese Hypertensive Patients. Journal of the American Society of Nephrology. 2019; 30 (10) 1991-1999; doi: 10.1681/ASN.2018101037 (IF 14.981; 5/90 in UROLOGY & NEPHROLOGY)
- Eric YF Wan, Esther YT Yu, WY Chin, Colman SC Fung, Daniel YT Fong, Edmond PH Choi, Anca KC Chan, Cindy LK Lam. Effect of Achieved Systolic Blood Pressure on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus - A Population-based Retrospective Cohort Study. Diabetes Care. 2018; 41 (6): 1134-1141 DOI: https://doi.org/10.2337/dc17-2443. (IF 17.155, 6/146 in Endocrinology & Metabolism)
Funding
Professor Wan has received funding and support from:
- National Natural Science Foundation of China (NSFC) – Excellent Young Scientist Fund (Hong Kong and Macau), Young Scientist Fund, China
- Research Grants Council (RGC), Hong Kong SAR
- Narcotics Division, Security Bureau, Beat Drugs Fund Regular Funding Scheme, Hong Kong SAR
- Food and Health Bureau, Hong Kong SAR
- Health and Medical Research Fund (HMRF), Hong Kong SAR
Selected Grants and Funding as Principal Investigator or Co-Principal Investigator:
Duration | Project Title | Source of funding | Amount Awarded: |
2023-2025 | Optimizing the frequency of complication monitoring for patients with Type 2 diabetes mellitus in primary care based on risk stratification | National Natural Science Foundation of China (NSFC) Excellent Young Scientists Fund (Hong Kong and Macau) | RMB¥2,000,000 |
2023-2024 | Short- and long-term burden of COVID-19 in substance abusers: A cohort study | Beat Drugs Fund Regular Funding Scheme, Narcotics Division, Security Bureau | HK$372,453 |
2021-2026 | The long term spill-over impact of COVID-19 on health and healthcare of patients with non-communicable diseases: an in-depth outcome and health economic evaluation. Disease (COVID-19). (Co-Chief of investigator) | Food and Health Bureau Commissioned Research on the Novel Coronavirus | HKD$9,334,600 |
2021-2023 | What is optimal blood pressure target for antihypertensive treatment? A target randomized controlled trial emulation using big data. | Health and Medical Research Fund | HKD$925,260 |
2021-2023 | A multinational big data Covid-19 Epidemiological Study on post-infection Outcomes (ACESO). (Co-PI) | RGC Collaborative Research Fund (CRF) Coronavirus Disease (COVID-19) and Novel Infectious Disease (NID) Research Exercise | HKD$9,691,060 |
2020-2022 | When should statin therapy be initiated for patients with diabetes mellitus - A target randomized controlled trial emulation using big data. Health and Medical Research Fund Research Fellowship Scheme. | Health and Medical Research Fund Research Fellowship Scheme | HKD$1,135,398 |
2021-2021 | The development of the Common Core course “Health Literacy: Things to know before consulting Dr. Google”. | Common Core Teaching Development Grant (TDG) Award | HKD$80,000 |
2019-2020 | Identifying and articulating the student learning experience in the MBBS 130 curriculum Enrichment Year | Teaching Development Grant (TDG) Award | HKD$100,000 |
Other Information
Seeking MPhil/PhD candidates
We are seeking highly organized and motivated graduate students to conduct research in the areas of medication safety, pharmacoepidemiology, epidemiology, public health and health intervention/service using big data cohort. We welcome any new research idea in these areas. For further information about the project and suitability, please email Professor Eric Wan (yfwan@hku.hk)
Regular Student Consultation Hours
Every Tuesday at 11:00am - 12:00pm
Office
1/F, Jockey Club Building for Interdisciplinary Research
5 Sassoon Road, Pokfulam
Hong Kong SAR, China